Research.Patient.info
Spinocerebellar ataxia type 3 research hub
2 indexed studies · 2 currently recruiting
- recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3
This study tests a new experimental drug, S233107, for adults living with spinocerebellar ataxia type 3 (SCA3). Because this is the first time the medicine is tested in people, researchers want to see if it is safe, how well the body handles it, and how it moves through spinal fluid.
France · Denmark · Spain - recruitingPHASE1, PHASE2
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
This study is testing a new drug called VO659 for people with certain genetic conditions affecting movement: Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, and Huntington's Disease. It's looking at how safe the drug is and how the body handles it. This is a very early stage trial.
Denmark · France · Germany